The use of ketamine as an antidepressant: a systematic review and meta‐analysis

E-ISSN： 1099-1077|30|3|152-163

ISSN： 0885-6222

Source： Human Psychopharmacology: Clinical And Experimental (Electronic), Vol.30, Iss.3, 2015-05, pp. : 152-163

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

ObjectiveThe current meta‐analysis examines the effects of ketamine infusion on depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder (BD).MethodsFollowing a systematic review of the literature, data were extracted from 21 studies (n = 437 receiving ketamine) and analysed at four post‐infusion time points (4 h, 24 h, 7 days and 12–14 days). The moderating effects of several factors were assessed including: repeat/single infusion, diagnosis, open‐label/participant‐blind infusion, pre–post/placebo‐controlled design and the sex of patients.ResultsEffect sizes were significantly larger for repeat than single infusion at 4 h, 24 h and 7 days. For single infusion studies, effect sizes were large and significant at 4 h, 24 h and 7 days. The percentage of males was a predictor of antidepressant response at 7 days. Effect sizes for open‐label and participant‐blind infusions were not significantly different at any time point.ConclusionsSingle ketamine infusions elicit a significant antidepressant effect from 4 h to 7 days; the small number of studies at 12–14 days post infusion failed to reach significance. Results suggest a discrepancy in peak response time depending upon primary diagnosis — 24 h for MDD and 7 days for BD. The majority of published studies have used pre–post comparison; further placebo‐controlled studies would help to clarify the effect of ketamine over time. Copyright © 2015 John Wiley & Sons, Ltd.